<DOC>
	<DOCNO>NCT01083966</DOCNO>
	<brief_summary>A recent study Plotkin et al . show bevacizumab ( Avastin ) treatment follow clinically meaningful hearing improvement , tumor-volume reduction , , , patient Vestibular Schwannoma ( VS ) risk complete hearing loss brain-stem compression grow VS. Because promise result preliminary study Bevacizumab significant experience safety dosage propose study , study offer safe treatment patient VS . Therefore , phase I clinical research trial test hypothesis Bevacizumab safely use direct intracranial superselective intraarterial infusion dose 10mg/kg ultimately enhance survival hear function patient VS .</brief_summary>
	<brief_title>Super-Selective Intraarterial Cerebral Infusion Bevacizumab ( Avastin ) Treatment Vestibular Schwannoma</brief_title>
	<detailed_description>Newer technique interventional neuroradiology allow selective delivery catheter higher arterial tree agent chemotherapy , deliver without risk adverse affect blindness . In fact , study Cornell develop new excite super selective intraarterial delivery treatment Retinoblastoma Malignant Glioma brain tumor little toxicity . Therefore , trial ask one simple question : Is safe deliver first dose Avastin intraarterially use super selective delivery technique instead standard intravenous route administration ? This increase amount drug get VS also spare adverse effect less selective delivery . During single dose intraarterial Avastin , also receive dose mannitol open blood brain barrier improve delivery agent tumor . After single dose Mannitol Avastin intraarterially , patient evaluate 4 week assess toxicity . If toxicity , go get MRI brain every two month ass response 12 month . After , subject do `` experimental '' aspect protocol . This Phase I trial design test safety single dose intraarterial delivery Avastin Mannitol , . To summarize : Current Standard Care : Surgery radiosurgery : IV Avastin Experimental portion proposal : Day 0 : Intraarterial Avastin single dose ( start 2mg/kg 10mg/kg ) Mannitol open blood brain barrier Day 28 ( every two month thereafter ) : MRI brain contrast Therefore experimental aspect treatment plan include : 1 . Subjects first treat Mannitol prior chemotherapy infusion ( Mannitol 25 % ; 3-10 mL/s 30seconds ) order disrupt blood brain barrier . This technique use several thousand patient previous study IA delivery chemotherapy malignant glioma . 2 . To add single intraarterial delivery ( SIACI ) Avastin VS. 3 . The dose escalation algorithm follow : We use single intracranial superselective intraarterial infusion Avastin , start dose 2mg/kg first three patient . Assuming dose limit toxicity first 28 day IA infusion , MRI brain perform . The dos escalate 4,6,8 finally 10mg/kg Phase I trial . Inclusion criterion Include : Males female , &gt; =18 year age , document Radiologic histologic diagnosis VS Both hematologic non-hematologic toxicity determine scored accord NCI Common Toxicity Criteria ( version 3.0 ) . Monitoring conduct post procedure history , neurological physical examination together serial blood count , prothrombin time ( PT ) , partial thromboplastin time ( PTT ) chemistry . Response evaluate 4 week via MRI injection contrast . The following evaluated every cycle , follow-up : neurological examination , physical examination , performance status , laboratory parameter review adverse reaction . Contrast enhance MRI ( MRI gadolinium preferable imaging study . The following subject take protocol : progressive disease ; experience dose-limiting toxicity ( DLT ) . Follow-up continue disease progression death . Survival measure time first dose IA Avastin® ( give start treatment cycle ) .</detailed_description>
	<mesh_term>Neurilemmoma</mesh_term>
	<mesh_term>Neuroma , Acoustic</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Male female patient &gt; = 18 year age . Patients document diagnosis unilateral bilateral VS base MRI evidence progressive vestibular schwannomas , consider poor candidate surgery radiation therapy decline treatment . Patients must Karnofsky performance status &gt; =60 % ( equivalent ECOG level 02 ) ( see Appendix A ; Performance Status Evaluation ) expect survival &gt; = three month . No chemotherapy two week prior treatment research protocol external beam radiation two week prior treatment research protocol . Patients must adequate hematologic reserve WBC &gt; =3000/mm3 , absolute neutrophil &gt; =1500/mm3 platelet &gt; =100,000/ mm3 . Patients Coumadin must platelet count &gt; =150,000/ mm3 . Preenrollment chemistry parameter must show : bilirubin &lt; 1.5X institutional upper limit normal ( IUNL ) ; AST ALT &lt; 2.5X IUNL creatinine &lt; 1.5X IUNL . Preenrollment coagulation parameter ( PT PTT ) must &lt; 1.5X IUNL . Patients must agree use medically effective method contraception period three month treatment period . A pregnancy test perform premenopausal female childbearing potential immediately prior entry research study . Previous treatment Avastin® . Women pregnant lactating . Women childbearing potential fertile men inform potential risk procreation participate research trial advise must use effective contraception period three month treatment period . Patients significant intercurrent medical psychiatric condition would place increased risk affect ability receive comply treatment posttreatment clinical monitoring include MRI gadolinium . Surgery ( include open biopsy ) , significant traumatic injury within 28 day prior randomization , anticipation need major surgery study treatment . Current recent ( within 10 day Avastin ) use aspirin ( &gt; 325 mg/day ) , full dose ( i.e. , therapeutic dose ) oral parenteral anticoagulant thrombolytic agent therapeutic purpose . Prophylactic use anticoagulant allow ( e.g. , warfarin ( 1 mg qd ) catheter prophylaxis , prophylactic low molecularweight heparin ( i.e. , enoxaparin [ ( 40mg QD0 ] ) . History evidence inherit bleed diathesis coagulopathy risk bleeding . Inadequately control hypertension ( blood pressure : systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg ) . Patients baseline urine dipstick proteinuria &gt; 2+ must undergo 24hours urine collection must demonstrate ≤ 1 g protein 24 hour . Clinically significant ( i.e. , active ) cardiovascular disease ( e.g. , cerebrovascular accident myocardial infarction within 6 month prior randomization ) , unstable angina , congestive heart failure ( NYHA Class ≥ II ) , serious cardiac arrhythmia uncontrolled medication may interfere administration study treatment . Serious nonhealing sound , active peptic ulcer , untreated bone fracture . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month enrollment . Known hypersensitivity Avastin excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Vestibular</keyword>
	<keyword>Schwannoma</keyword>
	<keyword>earing-loss</keyword>
	<keyword>brain-tumor</keyword>
	<keyword>Acoustic</keyword>
	<keyword>Neuroma</keyword>
</DOC>